Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families.[ Read More ]
The intrinsic value of one EHAB stock under the base case scenario is HIDDEN Compared to the current market price of 7.35 USD, Enhabit, Inc. is HIDDEN
Current Assets | 210 M |
Cash & Short-Term Investments | 27.4 M |
Receivables | 168 M |
Other Current Assets | 15 M |
Non-Current Assets | 1.22 B |
Long-Term Investments | 0 |
PP&E | 76.5 M |
Other Non-Current Assets | 1.15 B |
Current Liabilities | 138 M |
Accounts Payable | 7.6 M |
Short-Term Debt | 46.1 M |
Other Current Liabilities | 84 M |
Non-Current Liabilities | 594 M |
Long-Term Debt | 573 M |
Other Non-Current Liabilities | 21.5 M |
Revenue | 1.05 B |
Cost Of Revenue | 566 M |
Gross Profit | 480 M |
Operating Expenses | 442 M |
Operating Income | -47.6 M |
Other Expenses | 32.9 M |
Net Income | -80.5 M |
Net Income | -80.5 M |
Depreciation & Amortization | 30.9 M |
Capital Expenditures | -3.5 M |
Stock-Based Compensation | 8.9 M |
Change in Working Capital | 11.7 M |
Others | 112 M |
Free Cash Flow | 44.9 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
5 days ago
Nov 12, 2024
|
Bought 22.8 K USD
|
Bolton Jeffrey
Director |
+ 3000
|
7.6 USD |
1 week ago
Nov 08, 2024
|
Bought 49.3 K USD
|
Bolton Jeffrey
Director |
+ 6351
|
7.77 USD |
1 week ago
Nov 08, 2024
|
Bought 5.03 K USD
|
Bolton Jeffrey
Director |
+ 649
|
7.75 USD |
2 months ago
Aug 22, 2024
|
Bought 40 K USD
|
Bolton Jeffrey
Director |
+ 5000
|
8.01 USD |
3 months ago
Aug 09, 2024
|
Bought 41.4 K USD
|
Bolton Jeffrey
Director |
+ 5000
|
8.29 USD |
3 months ago
Aug 08, 2024
|
Bought 17.2 K USD
|
Bolton Jeffrey
Director |
+ 2000
|
8.6 USD |
6 months ago
May 17, 2024
|
Bought 83.3 K USD
|
Bolton Jeffrey
Director |
+ 10000
|
8.33 USD |
6 months ago
May 14, 2024
|
Bought 18 K USD
|
Hoeflinger Erin
Director |
+ 2000
|
9 USD |
6 months ago
May 10, 2024
|
Bought 82.4 K USD
|
Bolton Jeffrey
Director |
+ 10000
|
8.24 USD |
8 months ago
Mar 01, 2024
|
Sell 5.59 K USD
|
Langham Ronald Leroy JR
EVP Clinical Excel. & Strategy |
- 634
|
8.81 USD |
1 year ago
May 26, 2023
|
Bought 23.2 K USD
|
Bolton Jeffrey
Director |
+ 2000
|
11.61 USD |
1 year ago
May 22, 2023
|
Bought 120 K USD
|
SHAW L EDWARD JR
Director |
+ 10000
|
11.98 USD |
1 year ago
May 18, 2023
|
Bought 24.8 K USD
|
Hoeflinger Erin
Director |
+ 2100
|
11.82 USD |
1 year ago
May 18, 2023
|
Bought 120 K USD
|
Langham Ronald Leroy JR
EVP Clinical Excel. & Strategy |
+ 10000
|
11.99 USD |
1 year ago
May 17, 2023
|
Bought 23.6 K USD
|
Bolton Jeffrey
Director |
+ 2000
|
11.8 USD |
2 years ago
Nov 18, 2022
|
Bought 12.7 K USD
|
Bolton Jeffrey
Director |
+ 1000
|
12.69 USD |
2 years ago
Nov 09, 2022
|
Bought 25.5 K USD
|
Bolton Jeffrey
Director |
+ 2000
|
12.75 USD |
2 years ago
Nov 08, 2022
|
Bought 25.8 K USD
|
Bolton Jeffrey
Director |
+ 2000
|
12.89 USD |
2 years ago
Nov 08, 2022
|
Bought 5.78 K USD
|
HIGDON LEO I JR
Director |
+ 426
|
13.57 USD |
2 years ago
Nov 07, 2022
|
Bought 105 K USD
|
Rush Gregory S
Director |
+ 8300
|
12.69 USD |
2 years ago
Nov 04, 2022
|
Bought 21.4 K USD
|
Rush Gregory S
Director |
+ 1700
|
12.58 USD |
2 years ago
Aug 31, 2022
|
Bought 24.8 K USD
|
Brown-Stevenson Tina L.
director: |
+ 1550
|
15.99 USD |
2 years ago
Aug 18, 2022
|
Bought 13.5 K USD
|
Hoeflinger Erin
director: |
+ 970
|
13.9 USD |
2 years ago
Aug 18, 2022
|
Bought 82.1 K USD
|
Hoeflinger Erin
Director |
+ 6030
|
13.62 USD |
2 years ago
Aug 17, 2022
|
Bought 25 K USD
|
Marion Tanya Renee
Chief Human Resources Officer |
+ 1712
|
14.6 USD |
2 years ago
Aug 11, 2022
|
Bought 50.1 K USD
|
ELSON CHARLES M
director: |
+ 3700
|
13.55 USD |
2 years ago
Aug 08, 2022
|
Bought 13.6 K USD
|
MAUPIN JOHN E JR D D S
director: |
+ 1000
|
13.59 USD |
2 years ago
Aug 08, 2022
|
Bought 20.6 K USD
|
CURL YVONNE M
director: |
+ 1500
|
13.75 USD |
2 years ago
Aug 09, 2022
|
Bought 413 K USD
|
Jacobsmeyer Barbara Ann
President and CEO |
+ 30000
|
13.78 USD |
2 years ago
Aug 09, 2022
|
Bought 136 K USD
|
SHAW L EDWARD JR
director: |
+ 10000
|
13.64 USD |
2 years ago
Aug 04, 2022
|
Bought 37.1 K USD
|
HIGDON LEO I JR
director: |
+ 3000
|
12.37 USD |
2 years ago
Aug 04, 2022
|
Bought 176 K USD
|
LaMonica Susan
director: |
+ 15000
|
11.72 USD |
2 years ago
Aug 04, 2022
|
Bought 11.7 K USD
|
Bolton Jeffrey
director: |
+ 1000
|
11.74 USD |
2 years ago
Aug 03, 2022
|
Bought 61.1 K USD
|
HIGDON LEO I JR
director: |
+ 4500
|
13.57 USD |